GSK plc announced that China's National Medical Products Administration accepted for priority review its application for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma, based on significant efficacy results from the DREAMM-7 trial. This filing marks GSK's seventh major acceptance for Blenrep combinations in 2024, following prior approvals in other regions.